Biggest News Aggregation in the World
📰 Arnaud Delepine News

Page 7 - Arnaud Delepine News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Arnaud Delepine. Real-time updates on events, politics, business and more.

Sanofi : to help manufacture Moderna COVID-19 vaccine, supporting global supply demands

Message : Required fields BRIDGEWATER, N.J., April 26, 2021 /PRNewswire/ -- Sanofi has entered into an agreement with Moderna, under which Sanofi will help manufacture Moderna´s COVID-19 vaccine, supporting the COVID-19 pandemic and vaccine supply needs. Sanofi will leverage its established infrastructure and manufacturing expertise at its site in Ridgefield, NJ, to perform fill and finish of up to 200 million doses of Modernas COVID-19 vaccine, starting in September 2021. "Since the beginnin...
United States France General Eva Schaefer Jansen Arnaud Delepine Nicolas Kressmann Suzanne Greco

Sanofi: New Dupixent (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years

Sanofi: New Dupixent (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years as young as 6 years Nearly 30 data presentations at AAD and ESPD across clinical and real-world settings, including the impact of Dupixent on disease measures in uncontrolled moderate-to-severe atopic dermatitis Late-breaking Phase 2 data for rilzabrutinib, an investigational therapy for pemphigus vulgaris, a rare, debilitating autoimmune disease, to...
United States France General Eva Schaefer Jansen Sebastien Barbarot Suzanne Greco Arnaud Delepine

European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple ... SanofiApril 19, 2021 GMT European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma Approval based on Phase 3 IKEMA study demonstrating Sarclisa added to standard of care carfilzomib and dexamethasone reduced risk of disease progression or death by 47% in pa...
France General United States United Kingdom South Korea Eva Schaefer Jansen Suzanne Greco
Source: apnews.com

European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma

d the risk of progression or death by nearly half formed the basis for this important EC approval. " Sarclisa Efficacy and Safety Profile in Difficult-to-Treat Patients This approval is based on data from the Phase 3 IKEMA study, a randomized, multi-center, open label clinical trial that enrolled 302 patients with relapsed MM across 69 centers spanning 16 countries. The primary endpoint of IKEMA was progression free survival (PFS). While median PFS, defined as time to disease progression or d...
France General United States United Kingdom South Korea Eva Schaefer Jansen Suzanne Greco

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi's novel investigational IL-2

Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofis novel investigational IL-2 Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofis novel investigational IL-2 Early clinical results are consistent with preclinical studies and suggest THOR-707 (SAR444245) may promote an anti-tumor immune response without alpha-mediated side effects, both alone and in combination with anti-PD-1 THOR-707, a precisely PEGylated,...
United States France General Eva Schaefer Jansen Arnaud Delepine Suzanne Greco Felix Lauscher

Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early ... SanofiMarch 15, 2021 GMT Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival                                                                         �...
France General United Kingdom United States South Korea Eva Schaefer Jansen Suzanne Greco
Source: apnews.com

Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate

Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels Expected to enroll 415 participants; interim results expected in Q3 2021 In parallel, preclinical studies are underway to evaluate additional mRNA candidates against emerging SARS-CoV-2 variants PARIS and LEXINGTON, MASS. - March 12, 2021 - Sanofi Pasteur, the vaccines g...
United States France General Eva Schaefer Jansen Arnaud Delepine Nicolas Kressmann Suzanne Greco

Investegate |Sanofi Announcements | Sanofi: Sanofi's Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members

Sanofi Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members Paris, France – March 3, 2021 – At its meeting on March 3, 2021, Sanofi’s Board of Directors has decided to propose, on the occasion of its next...
United States France General Arnaud Delepine Suzanne Greco Felix Lauscher Serge Weinberg

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science